Zealand Announces Collaboration with Eli Lilly - - BioPharm International

ADVERTISEMENT

Zealand Announces Collaboration with Eli Lilly



Zealand Pharma, a biopharmaceutical company based in Copenhagen specializing in peptides, has formed a peptide drug R+D collaboration agreement with Eli Lilly.

Under the agreement, Zealand will collaborate with Eli Lilly in the design and development of peptide therapeutics for the treatment of Type 2 diabetes and obesity. The companies will share in the funding, risk, and reward of the program. Future expansion of the collaboration to additional drug targets and disease areas is possible. No financial terms of the agreement have been disclosed.

Source: Zealand Pharma

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis and GSK Trade Assets
April 22, 2014
Lilly to Acquire Novartis Animal Health
April 22, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines

Click here